Phase I/II Study of Osimertinib With Bevacizumab in EGFR-mutated, T790M-positive Patients With Progressed EGFR-TKIs: West Japan Oncology Group 8715L (WJOG8715L)
In: Clinical Lung Cancer, Jg. 20 (2019), Heft 4, S. e492-e494
academicJournal
Zugriff:
Titel: |
Phase I/II Study of Osimertinib With Bevacizumab in EGFR-mutated, T790M-positive Patients With Progressed EGFR-TKIs: West Japan Oncology Group 8715L (WJOG8715L)
|
---|---|
Autor/in / Beteiligte Person: | Akamatsu, Hiroaki ; Teraoka, Shunsuke ; Morita, Satoshi ; Katakami, Nobuyuki ; Tachihara, Motoko ; Daga, Haruko ; Yamamoto, Nobuyuki ; Nakagawa, Kazuhiko ; AstraZeneca ; KK ; Pharmaceutical, Chugai ; Nippon Boehringer Ingelheim Co Ltd ; Japan, Pfizer ; West Japan Oncology Group Data Center ; Wakayama Medical University |
Link: | |
Zeitschrift: | Clinical Lung Cancer, Jg. 20 (2019), Heft 4, S. e492-e494 |
Veröffentlichung: | Elsevier BV, 2019 |
Medientyp: | academicJournal |
ISSN: | 1525-7304 |
DOI: | 10.1016/j.cllc.2019.03.002 |
Schlagwort: |
|
Sonstiges: |
|